Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.
Carlos Martin
Advertisement
Strategic Advisor, Rocket Pharmaceuticals
Articles by Carlos Martin
Advertisement
Latest Updated Articles
From Lab to Market: Tracking Today’s Shifting Pathways for BiotechPublished: September 17th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Study Claims Ozempic Lowers Biological Age
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
How will DTC Programs Impact PBMs?
5
